Two‐year abrocitinib in atopic dermatitis: Are we reaching the new targets?
Journal of the European Academy of Dermatology and Venereology · 2026-08 · 40 (8) · 1294-1295
DOI: 10.1111/jdv.70534 ↗At a glance
Editorial in Journal of the European Academy of Dermatology and Venereology, published online on 2026-07-31. Written by Axel De Greef and 1 co-authors. Institution: Department of Dermatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium. 5 references. The full text is freely available in PubMed Central.
Abstract (original language)
Není k dispozici žádný abstrakt.
Authors and institutions
- Department of Dermatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium.
- Institute of Experimental and Clinical Research (IREC), Pneumology, ENT and Dermatology Pole (LUNS), Université catholique de Louvain (UCLouvain), Brussels, Belgium.
ORCID profiles: Axel De Greef, Marie Baeck
Cite
APA
De Greef, A., & Baeck, M. (2026). Two‐year abrocitinib in atopic dermatitis: Are we reaching the new targets?. Journal of the European Academy of Dermatology and Venereology, 40(8), 1294-1295. https://doi.org/10.1111/jdv.70534
Vancouver
De Greef A, Baeck M. Two‐year abrocitinib in atopic dermatitis: Are we reaching the new targets?. Journal of the European Academy of Dermatology and Venereology. 2026;40(8):1294-1295. doi:10.1111/jdv.70534
BibTeX
@article{DeGreef2026,
author = {De Greef, Axel and Baeck, Marie},
title = {Two‐year abrocitinib in atopic dermatitis: Are we reaching the new targets?},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2026},
volume = {40},
number = {8},
pages = {1294--1295},
doi = {10.1111/jdv.70534}
}
EUVIMED